Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 9/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665117 | 0.89 | MAPT (0.75) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL27180717 | 0.89 | KMT2A (0.70) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL30926609 | 0.89 | KMT2A (0.70) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL10186956 | 0.89 | NR3C1 (0.66) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL29978195 | 0.87 | L3MBTL1 (0.70) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL662400 | 0.87 | L3MBTL1 (0.70) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL663265 | 0.85 | KMT2A (0.74) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL14601696 | 0.85 | KMT2A (1.00) | NR3C1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL18363031 | 0.85 | KMT2A (0.73) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30926751 | 0.85 | KMT2A (0.64) | NR3C1KMT2AMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-9862714-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170066755-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9416101-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | NR3C1 2079/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20170066755-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | NR3C1 2079/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | NR3C1 2079/4885KMT2A 3839/4885MEN1 4226/4885 |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | NR3C1 2079/4885KMT2A 3839/4885MEN1 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.